Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7811435 | 1.00 | FAP (0.30) | FAPUSP2ESR1AADATKDM4E | |
| SCHEMBL8311603 | 1.00 | FAP (0.30) | FAPUSP2ESR1AADATKDM4E | |
| SCHEMBL9486743 | 1.00 | FAP (0.30) | FAPUSP2ESR1AADATKDM4E | |
| SCHEMBL4523110 | 1.00 | FAP (0.30) | FAPUSP2ESR1AADATKDM4E | |
| SCHEMBL8311599 | 1.00 | FAP (0.30) | FAPUSP2ESR1AADATKDM4E | |
| SCHEMBL7811433 | 1.00 | FAP (0.30) | FAPUSP2ESR1AADATKDM4E | |
| SCHEMBL22582139 | 0.96 | USP2 (0.31) | USP2ESR1KDM4E | |
| SCHEMBL16673765 | 0.77 | — | — | |
| SCHEMBL19486294 | 0.74 | — | — | |
| SCHEMBL9470709 | 0.74 | USP2 (0.37) | USP2ESR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110372248-B | Preparation method of anti-mud agent suitable for high-mud-content concrete | 北京工业大学 | 2021-08-13 | — | — | CN | claimed |
| CN-109761871-B | Synthetic method of aztreonam monocyclic parent nucleus | 山东昌邑四方医药化工有限公司 | 2020-11-24 | — | — | CN | claimed |
| US-20200339507-A1 | METHODS OF SYNTHESIZING AZTREONAM DERIVATIVES | ARIXA PHARMACEUTICALS, INC. (US) | 2020-10-29 | — | — | US | claimed |
| WO-2020219258-A1 | METHODS OF SYNTHESIZING AZTREONAM DERIVATIVES | ARIXA PHARMACEUTICALS, INC. (US) | 2020-10-29 | — | — | WO | claimed |
| WO-2026107208-A1 | COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12516048-B2 | B-lactam compounds, their preparation and use as antibacterial agents | NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) | 2026-01-06 | — | — | US | disclosed |
| US-20250221408-A1 | COMPOSITION | EARTH CORPORATION (JP) | 2025-07-10 | — | — | US | disclosed |
| EP-4473837-A1 | COMPOSITION | Earth Corporation (JP) | 2024-12-11 | — | — | EP | disclosed |
| EP-3978472-B1 | BIARYL MONABACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-115210231-B | Monocyclic lactams, process for their preparation and their use as antibacterial agents | 宁夏农林科学院 | 2024-10-08 | — | — | CN | disclosed |
| CN-118695780-A | Composition and method for producing the same | 阿斯制药株式会社 | 2024-09-24 | — | — | CN | disclosed |
| CN-108368040-B | Diaryl monocyclic beta-lactam compounds and methods for their use in the treatment of bacterial infections | 默沙东有限责任公司 | 2024-08-23 | — | — | CN | disclosed |
| US-4483797-A | (S)-3-Isocyanato-2-oxo-1-azetidinesulfonic acids | E. R. SQUIBB & SONS, INC. (US) | 1984-11-20 | — | — | US | disclosed |
| US-4443374-A | Process for preparing (3S)-3-[[(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]-acetyl]amino]-2-oxo-1-azetidinesulfonic acid, and 4-substituted derivatives | E. R. SQUIBB & SONS, INC. (US) | 1984-04-17 | — | — | US | disclosed |
| EP-0097352-A2 | Process for the preparation of azetidine sulfonic acids | E.R. Squibb & Sons, Inc. (US) | 1984-01-04 | — | — | EP | disclosed |
| EP-0096297-A2 | Process for the preparation of 1-sulfo-2-oxoazetidine derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-12-21 | — | — | EP | disclosed |
| EP-0096296-A2 | 1-Sulfo-2-oxoazetidine derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-12-21 | — | — | EP | disclosed |
| EP-0086556-A1 | Process for preparing (3S)-3-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)-acetyl)amino)-2-oxo-1-azetidinesulfonic acid and 4-substituted derivatives | E.R. Squibb & Sons, Inc. (US) | 1983-08-24 | — | — | EP | disclosed |
| US-4386034-A | Sulfamated amino acid amides | E. R. SQUIBB & SONS, INC. (US) | 1983-05-31 | — | — | US | disclosed |
| EP-0048953-A2 | Beta-lactam antibiotics | E.R. Squibb & Sons, Inc. (US) | 1982-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339507-A1 | METHODS OF SYNTHESIZING AZTREONAM DERIVATIVES | DTYMK, TYMS, TYMP | FAP 4141/4885USP2 2913/4885ESR1 3282/4885 |
| US-20250221408-A1 | COMPOSITION | GGPS1, PGGT1B, HBG2 | FAP 4302/4885USP2 4207/4885ESR1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.